Endocyte Inc. (ECYT)
Symbol Info
Listed Symbol ECYT
Name Endocyte Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2017-12-31
Latest Fiscal Revenue $69,500
Latest Fiscal EPS $-1.26
Price Info
21 Day Moving Average $23.7833
21 Day EMA $23.720290
50 Day Moving Average $22.6826
50 Day EMA $22.541590
200 Day EMA $16.695870
200 Day Moving Average 16.189530
52 Week High $24.00
52 Week Low $2.81
52 Week Change $469.833700
Alpha 0.055412
Beta 0.1168
Standard Deviation 0.362021
R2 0.000116
Periods 60
Share Information
10 Day Average Volume 1,889,765
20 Day Average Volume 2,182,957
30 Day Average Volume 2,012,800
50 Day Average Volume 3,376,556
Outstanding Shares 82,097,630
Float Shares 79,929,463
Percent Float 97.36%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 306
Institute Holdings Date 2018-11-30
Institute Bought Previous 3 Months 9,307,594
Institute Holdings Percent 94.600000
Institute Sold Previous 3 Months 7,792,181
Insider Holdings Date 2018-11-30
Insider Bought Previous 3 Months -
Insider Holdings Percent 3.10%
Insider Sold Previous 3 Months 88,732
Insiders Shares Owned 2,168,167
Price Change
7 Day Price Change $0.1499996
7 Day Percent Change 0.63%
21 Day Price Change $0.3600006
21 Day Percent Change 1.52%
30 Day Price Change $0.3899994
30 Day Percent Change 1.65%
Month To Date Price Change $0.3600
Month To Date Percent 1.52%
90 Day Price Change $6.459999
90 Day Percent Change 36.85%
Quarter To Date $6.230000
Quarter To Date Percent 35.08%
180 Day Price Change $9.870000
180 Day Percent Change 69.90%
200 Day Price Change $10.690000
200 Day Percent Change 80.38%
Year To Date $19.710000
Year To Date Percent 460.51%
Profile
Description Endocyte Inc is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.
Details
Issue Type CS
Market Cap $1,969,522,144
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding -
CEO Michael Sherman
Employees 44
Last Audit UQ
Classification
CIK 0001235007
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 3000 Kent Avenue
Suite A1-100
West Lafayette, IN 47906
Website http://www.endocyte.com
Facisimile +1 765 463-9271
Telephone +1 765 463-7175
Email michael@sternir.com
Key Ratios
Profitability
EBIT Margin -21,098.1
EBITDA Margin -20,461.6
Pre-Tax Profit Margin -40,067.3
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $128,175
Revenue Per Share $0.0016
Revenue 3 Years $14.99
Revenue 5 Years $-78.11
Valuation Measures
PE Ratio -
Enterprise Value $1,625,311,652
Price To Sales 15,365.884000
Price To Free Cash -48
PE High Last 5 Years -
Price To Book 5.7
Price To Cash Flow 7.7
PE Low Last 5 Years -
Price To Tangible Book 5.7
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 45.8
Leverage Ratio 1.0
Quick Ratio 44.9
Long Term Debt To Capital -
Assets
Receivables Turnover 1.8
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -17.89
Return On Equity -18.42
Return On Capital -18.42
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
ECYT
Endocyte, ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191020 21:11:07